Market revenue in 2023 | USD 54.6 million |
Market revenue in 2030 | USD 140.2 million |
Growth rate | 14.4% (CAGR from 2023 to 2030) |
Largest segment | (crispr)/cas9 |
Fastest growing segment | (CRISPR)/Cas9 |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
(crispr)/cas9 was the largest segment with a revenue share of 46.15% in 2024. Horizon Databook has segmented the Argentina genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
Argentina's genome editing market is driven by factors such as the presence of a rich agricultural heritage and strong expertise in biotechnology that is fueling innovation in genetic engineering for crop improvement, supportive government policies, and investments in R&D to encourage the adoption of advanced genetic technologies, and a growing demand for sustainable agriculture and bio-based solutions. In addition, collaborations among academia, industry, and government foster knowledge exchange & technology transfer, boosting market growth.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account